Ovarian Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Ovarian Cancer, including details on symptoms, causes, treatment, information.

Volume 5 (2008), Issue 12 (December)

1. Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancers A Gynecologic Oncology Group study.
   Gynecol Oncol, 111(3): 487-95. [Abstract] [Full-text]
2. Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer.
   Gynecol Oncol, 111(3): 467-73. [Abstract] [Full-text]
3. Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer.
   Gynecol Oncol, 111(3): 461-6. [Abstract] [Full-text]
4. A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study.
   Gynecol Oncol, 111(3): 455-60. [Abstract] [Full-text]
5. Role of microRNAs in drug-resistant ovarian cancer cells.
   Gynecol Oncol, 111(3): 478-86. [Abstract] [Full-text]
6. The use of bevacizumab in refractory ovarian granulosa-cell carcinoma with symptomatic relief of ascites: a case report.
   Gynecol Oncol, 111(3): 527-9. [Abstract] [Full-text]
7. Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer.
   Gynecol Oncol, 111(3): 530-2. [Abstract] [Full-text]
8. Is there any possibility of fertility-sparing surgery in patients with clear-cell carcinoma of the ovary?
   Gynecol Oncol, 111(3): 523-6. [Abstract] [Full-text]
9. Luteinized thecoma associated with sclerosing peritonitis--conservative surgical approach followed by corticosteroid and GnRH agonist treatment--a case report.
   Gynecol Oncol, 111(3): 540-3. [Abstract] [Full-text]
10. Cauda equina syndrome due to leptomeningeal carcinomatosis of the ovary.
    Gynecol Oncol, 111(3): 544-5. [Abstract] [Full-text]
11. Thalidomide-induced reversible interstitial pneumonitis in a patient with recurrent ovarian cancer.
    Gynecol Oncol, 111(3): 546-8. [Abstract] [Full-text]
12. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers.
    Clin Chem, 54(12): e11-79. [Abstract] [Full-text]
13. Elevation of seprase expression and promotion of an invasive phenotype by collagenous matrices in ovarian tumor cells.
    Int J Cancer, 124(1): 27-35. [Abstract] [Full-text]
14. Ovarian epithelial dysplasia after ovulation induction: time and dose effects.
    Hum Reprod, 24(1): 132-8. [Abstract] [Full-text]
15. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer.
    J Clin Oncol, 26(35): 5761-6. [Abstract] [Full-text]
16. G-protein-coupled receptor 30 and estrogen receptor-alpha are involved in the proliferative effects induced by atrazine in ovarian cancer cells.
    Environ Health Perspect, 116(12): 1648-55. [Abstract] [Full-text]
17. Overexpression of RhoA enhances peritoneal dissemination: RhoA suppression with Lovastatin may be useful for ovarian cancer.
    Cancer Sci, 99(12): 2532-9. [Abstract] [Full-text]
18. Efficacy assessment of sustained intraperitoneal paclitaxel therapy in a murine model of ovarian cancer using bioluminescent imaging.
    Br J Cancer, 99(12): 2037-43. [Abstract] [Full-text]
19. Loss of estrogen receptor beta isoform expression and its correlation with aberrant DNA methylation of the 5'-untranslated region in human epithelial ovarian carcinoma.
    Cancer Sci, 99(12): 2365-72. [Abstract] [Full-text]
20. Involvement of thioredoxin-binding protein 2 in the antitumor activity of CD437.
    Cancer Sci, 99(12): 2485-90. [Abstract] [Full-text]
21. KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer.
    Br J Cancer, 99(12): 2020-8. [Abstract] [Full-text]
22. MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer.
    Cancer Res, 68(24): 10307-14. [Abstract] [Full-text]
23. Molecular mechanisms of patupilone resistance.
    Cancer Res, 68(24): 10197-204. [Abstract] [Full-text]
24. An epigenetic marker panel for screening and prognostic prediction of ovarian cancer.
    Int J Cancer, 124(2): 387-93. [Abstract] [Full-text]
25. Implication of the Akt2/survivin pathway as a critical target in paclitaxel treatment in human ovarian cancer cells.
    Cancer Lett, 273(2): 257-65. [Abstract] [Full-text]
26. Trends in incidence of and mortality from uterine and ovarian cancer in Mid and South Limburg, The Netherlands, 1986-2003.
    Eur J Cancer Prev, 18(1): 85-9. [Abstract] [Full-text]
27. Expression profile of mammalian microRNAs in endometrioid adenocarcinoma.
    Eur J Cancer Prev, 18(1): 50-5. [Abstract] [Full-text]
28. Time to stop ovarian cancer screening in BRCA1/2 mutation carriers?
    Int J Cancer, 124(4): 919-23. [Abstract] [Full-text]
29. The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer.
    Int J Cancer, 124(4): 806-15. [Abstract] [Full-text]
30. Dicer, Drosha, and outcomes in patients with ovarian cancer.
    N Engl J Med, 359(25): 2641-50. [Abstract] [Full-text]
31. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial.
    Oncology, 76(1): 49-54. [Abstract] [Full-text]
32. A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma.
    Gynecol Oncol, 112(1): 6-10. [Abstract] [Full-text]
33. Aggressive and complex surgery for advanced ovarian cancer: an economic analysis.
    Gynecol Oncol, 112(1): 16-21. [Abstract] [Full-text]
34. Ovarian carcinoma cells influence differentiation of Lin-CD45RA- dendritic cell precursors into two mature subtypes in vitro.
    Gynecol Oncol, 112(1): 199-204. [Abstract] [Full-text]
35. Uptake of clinical genetic testing for ovarian cancer in Ontario: a population-based study.
    Gynecol Oncol, 112(1): 68-72. [Abstract] [Full-text]
36. Interval debulking surgery for advanced epithelial ovarian cancer: a Cochrane systematic review.
    Gynecol Oncol, 112(1): 257-64. [Abstract] [Full-text]
37. The clinical significance of hepatic parenchymal metastasis in patients with primary epithelial ovarian cancer.
    Gynecol Oncol, 112(1): 28-34. [Abstract] [Full-text]
38. Cyr61, a member of ccn (connective tissue growth factor/cysteine-rich 61/nephroblastoma overexpressed) family, predicts survival of patients with endometrial cancer of endometrioid subtype.
    Gynecol Oncol, 112(1): 229-34. [Abstract] [Full-text]
39. A serum based analysis of ovarian epithelial tumorigenesis.
    Gynecol Oncol, 112(1): 47-54. [Abstract] [Full-text]
40. Urinary levels of Bcl-2 are elevated in ovarian cancer patients.
    Gynecol Oncol, 112(1): 60-7. [Abstract] [Full-text]
41. Synergistic cytotoxicity of interferonalpha-2b and interleukin-2 in combination with PBMC against ovarian cancer: development of an experimental model for cellular therapy.
    Gynecol Oncol, 112(1): 192-8. [Abstract] [Full-text]
42. Dietary aspirin decreases the stage of ovarian cancer in the hen.
    Gynecol Oncol, 112(1): 166-70. [Abstract] [Full-text]
43. Platinum compounds 30 years after the introduction of cisplatin: implications for the treatment of ovarian cancer.
    Gynecol Oncol, 112(1): 275-81. [Abstract] [Full-text]
44. Phase II trial of carboplatin and distearoylphosphatidylcholine pegylated liposomal doxorubicin (Lipo-Dox) in recurrent platinum-sensitive ovarian cancer following front-line therapy with paclitaxel and platinum.
    Gynecol Oncol, 112(1): 35-9. [Abstract] [Full-text]
45. CYP1B1 expression in ovarian cancer in the laying hen Gallusdomesticus.
    Gynecol Oncol, 112(1): 171-8. [Abstract] [Full-text]
46. Clinical significance of circulating tumor cells detected by an invasion assay in peripheral blood of patients with ovarian cancer.
    Gynecol Oncol, 112(1): 185-91. [Abstract] [Full-text]
47. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform.
    Gynecol Oncol, 112(1): 55-9. [Abstract] [Full-text]
48. Estrone sulfatase activity in patients with advanced ovarian cancer.
    Gynecol Oncol, 112(1): 205-9. [Abstract] [Full-text]
49. Stage IV ovarian cancer: disease site-specific rationale for postoperative treatment.
    Gynecol Oncol, 112(1): 22-7. [Abstract] [Full-text]
50. TP53, BCL-2 and BAX analysis in 199 ovarian cancer patients treated with taxane-platinum regimens.
    Gynecol Oncol, 112(1): 179-84. [Abstract] [Full-text]
51. Prospective evaluation of prognostic significance of the tumor-free distance from uterine serosa in surgically staged endometrial adenocarcinoma.
    Gynecol Oncol, 112(1): 146-9. [Abstract] [Full-text]
52. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis.
    Gynecol Oncol, 112(1): 265-74. [Abstract] [Full-text]
53. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass.
    Gynecol Oncol, 112(1): 40-6. [Abstract] [Full-text]
54. Immunoprofile of adenocarcinomas of the endometrium, endocervix, and ovary with mucinous differentiation.
    Appl Immunohistochem Mol Morphol, 17(1): 8-11. [Abstract] [Full-text]
55. Surgical treatment for patients with different origins of Krukenberg tumors: outcomes and prognostic factors.
    Eur J Surg Oncol, 35(1): 92-7. [Abstract] [Full-text]
56. Metabolic syndrome after risk-reducing salpingo-oophorectomy in women at high risk for hereditary breast ovarian cancer: a controlled observational study.
    Eur J Cancer, 45(1): 82-9. [Abstract] [Full-text]
57. Cervical, endometrial and ovarian cancers among immigrants in Sweden: importance of age at migration and duration of residence.
    Eur J Cancer, 45(1): 107-18. [Abstract] [Full-text]
58. Epidemiology of ovarian cancer.
    Methods Mol Biol, 472: 413-37. [Abstract] [Full-text]
59. Regulator of G-protein signalling expression and function in ovarian cancer cell lines.
    Cell Mol Biol Lett, 14(1): 153-74. [Abstract] [Full-text]
60. Chromosomes 6 and 18 induce neoplastic suppression in epithelial ovarian cancer cells.
    Int J Cancer, 124(5): 1037-44. [Abstract] [Full-text]
61. Functional significance of VEGFR-2 on ovarian cancer cells.
    Int J Cancer, 124(5): 1045-53. [Abstract] [Full-text]
62. Monitoring of IL-10 in the serum of patients with advanced ovarian cancer: results from a prospective pilot-study.
    Cytokine, 45(1): 8-11. [Abstract] [Full-text]
63. Cause-specific survival for women diagnosed with cancer during pregnancy or lactation: a registry-based cohort study.
    J Clin Oncol, 27(1): 45-51. [Abstract] [Full-text]
64. A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary.
    Am J Surg Pathol, 33(1): 14-21. [Abstract] [Full-text]

© 2004-2010 Ovarian Cancer Research Today. All Rights Reserved.